ArticleOncotarget2017
Lasp1 promotes malignant phenotype of non-small-cell lung cancer via inducing phosphorylation of FAK-AKT pathway.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- LASP1 mediates ADAM17 upregulation in high glucose to promote fibrosis in diabetic kidneys.Diabetologia · 2026Article
- Pharmacogenomic Drug-Target Network Analysis Reveals Similarity Profiles Among FDA-Approved Cancer Drugs.Pharmaceutics · 2025Article
- Analysis of TGFβ1-Induced activin A gene expression in kidney mesangial cells.Frontiers in molecular biosciences · 2025Article
- The therapeutic potential of RNA m(6)A in lung cancer.Cell communication and signaling : CCS · 2024Review
- E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer.Oncogene · 2024Article
- TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.Breast cancer research : BCR · 2024Article
- ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with MDM2.Cancer science · 2023Article
- SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis.Diagnostics (Basel, Switzerland) · 2023Article
- THSD7A Positivity Predicts Poor Survival and Is Linked to High FAK Expression and FGFR1-Wildtype in Female Patients with Squamous Cell Carcinoma of the Lung.International journal of molecular sciences · 2023Article
- TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs.Cell death & disease · 2023Article
- LASP1 in Cellular Signaling and Gene Expression: More than Just a Cytoskeletal Regulator.Cells · 2022Review
- MiR-4521 plays a tumor repressive role in growth and metastasis of hepatocarcinoma cells by suppressing phosphorylation of FAK/AKT pathway via targeting FAM129A.Journal of advanced research · 2022Article
- Network pharmacology and experimental analysis to reveal the mechanism of Dan-Shen-Yin against endothelial to mesenchymal transition in atherosclerosis.Frontiers in pharmacology · 2022Article
- Long non‑coding RNA H19 regulates LASP1 expression in osteosarcoma by competitively binding to miR‑29a‑3p.Oncology reports · 2021Article
- HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance.Journal of experimental & clinical cancer research : CR · 2021Article
- LASP1 Induces Epithelial-Mesenchymal Transition in Lung Cancer through the TGF-Canadian respiratory journal · 2021Article
- LINC01503/miR-342-3p facilitates malignancy in non-small-cell lung cancer cells via regulating LASP1.Respiratory research · 2020Article
- Article
- LASP1 promotes proliferation, metastasis, invasion in head and neck squamous cell carcinoma and through direct interaction with HSPA1A.Journal of cellular and molecular medicine · 2020Article
- Circular RNAs and gastrointestinal cancers: Epigenetic regulators with a prognostic and therapeutic role.Critical reviews in oncology/hematology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lasp1 (LIM and SH3 domain protein 1) promotes tumor proliferation and invasion in multiple cancer entities including non-small cell lung cancer (NSCLC). However, the molecular mechanism is uncertain to date. In the present study, using immunohistochemistry, we found that Lasp1 expression was significantly correlated with tumor size (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.